China unveils 15th five-year pharma plan; innovative drug stocks surge on targets
On September 21, Chinese A-share markets opened higher, with innovative drug and CRO stocks surging after ten government departments released the 15th Five-Year Plan for Pharmaceutical Industry Development on September 18. The plan targets over 3.5 trillion yuan in revenue for large pharmaceutical firms by 2030, annual innovative drug industry growth above 20%, and first-in-class drugs reaching 25% of global share. Separately, PCB stocks rose on raw material price re-quoting, MLCC stocks gained on AI-driven shortages, and humanoid robot stocks rebounded on Tesla Optimus production line news.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China A-Share Market: Innovative Drug Stocks Surge, PCB and MLCC Concepts Rise on Policy and AI Demand
On September 21, China's A-share major indices opened higher. The innovative drug (886015) and CRO (885927) concepts surged, with Nanhua Bio (000504) hitting its third consecutive daily limit, and Harbin Pharm (600664) and Xinhua Pharma (000756) also hitting limits. This followed a September 18 joint announcement by ten Chinese government departments, including the Ministry of Industry and Information Technology, of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development'. The plan targets over 3.5 trillion yuan in revenue for large pharmaceutical firms by 2030, with innovative drug industry scale growing over 20% annually and first-in-class drugs reaching 25% of the global share. Separately, the PCB concept rose as multiple brokerages noted that PCB manufacturers have started re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. The MLCC concept was active, driven by reports of AI-fueled shortages of high-capacity models causing spot price surges. The humanoid robot concept rebounded after a drone video showed Tesla's Optimus production line structure in Texas nearing completion, targeting 10 million units annual capacity by 2027. Stock Hua Ci (001216) hit its fifth consecutive daily limit, with the company attributing the rise to market speculation on its zirconia business, noting that supply to Chaozhou Three-Circle is still in small-scale validation.
Read sourceChina's Innovative Drug Stocks Surge on New Five-Year Plan; PCB, MLCC Sectors Rally
On September 21, A-share major indices opened higher, with innovative drug (886015) and CRO concept (885927) stocks leading gains. Nanhua Bio (000504) hit its third consecutive daily limit, while Harbin Pharmaceutical (600664) and Xinhua Pharma (000756) also hit the daily limit. The rally follows the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese ministries, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, 20%+ annual growth for innovative drugs, and 25%+ global share for first-in-class drugs. Separately, PCB concept stocks rose after multiple brokerages noted that manufacturers have started re-quoting due to rising raw material prices, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC concept stocks also gained on reports of AI-driven shortages and price surges. Humanoid robot concept stocks rebounded after a drone video suggested Tesla's Optimus production line in Texas may be near structural completion, targeting 10 million units annual capacity by 2027. Gaming and memory chip concepts also saw intraday spikes.
Read sourceChina A-Share Market: Innovative Drug Stocks Surge, PCB and MLCC Sectors Rally on Policy and Price Hikes
On September 21, China's A-share markets opened higher, with notable gains in innovative drug and CRO concept stocks. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The rally follows the September 18 release of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments, which sets targets including over 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, annual innovative drug industry growth above 20%, and 25% global share for first-in-class drugs. Separately, PCB stocks rose after multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC concept stocks also gained, driven by reports of AI-driven shortages causing spot prices to surge several-fold. Humanoid robot concept stocks rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceShow 17 older updatesHide older updates
China A-Share Market: Innovative Drug Stocks Surge, PCB and MLCC Sectors Rally on Policy and Price Hikes
On September 21, China's A-share markets opened higher, with the innovative drug and CRO concept sectors leading gains. Nanhua Bio (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten central government departments, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth for innovative drugs. Separately, the PCB sector rose after multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for profitability. MLCC concept stocks also gained on reports of AI-driven shortages causing price surges. The humanoid robot concept rebounded after a drone video showed Tesla's Optimus production line in Texas nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina A-Share Market: Innovative Drug Stocks Surge, PCB and MLCC Sectors Rally on Policy and AI Demand
On September 21, China's A-share major indices opened higher, with innovative drug and CRO concepts leading gains. Nanhua Bio (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The rally follows the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese ministries, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth for innovative drug industry scale. Separately, PCB stocks rose as multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC concept stocks also gained, driven by reports of AI-driven shortages causing spot prices to surge several times. The humanoid robot concept rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina's Innovative Drug Stocks Surge on Ten-Ministry Plan; PCB, MLCC, Humanoid Robot Shares Also Rally
On September 21, Chinese A-share markets opened higher, with innovative drug and CRO concepts leading gains. Nanhua Bio (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten ministries including MIIT and NDRC, which set targets for 2030: over 3.5 trillion yuan in revenue for large-scale pharmaceutical firms, 20%+ annual growth in innovative drug industry scale, 25%+ global share of first-in-class drugs, 200+ innovative medical device approvals, and 20+ 100-billion-yuan pharmaceutical industrial parks. Separately, PCB stocks rose as brokerages noted raw material price hikes have triggered re-quoting, with Q3 2026 seen as a profit inflection point. MLCC stocks gained on AI-driven shortages of high-capacity models, with spot prices surging several-fold. Humanoid robot concept stocks rebounded after a drone video showed Tesla's Optimus production line in Texas nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese A-Share Markets Open Higher; Innovative Drug Stocks Rally on New Ten-Ministry Plan
Chinese A-share markets opened higher on September 21, with the MLCC concept, CRO concept, media, semiconductor, and military electronics sectors leading gains, while grain, coal, oil and gas, precious metals, and tourism sectors declined. Innovative drug and CRO concepts saw a notable rally, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit up, and Harbin Pharmaceutical, Xinhua Pharmaceutical, and others also rising. The move follows the September 18 release of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese ministries including the Ministry of Industry and Information Technology and the National Development and Reform Commission. The plan sets targets for 2030: revenue of over 3.5 trillion yuan for large-scale pharmaceutical firms, annual innovative drug industry growth of over 20%, first-in-class drugs accounting for over 25% globally, over 200 innovative medical device approvals, and 20 pharmaceutical industrial parks with over 100 billion yuan in output. Separately, PCB stocks rose on reports of price renegotiations amid rising raw material costs, with analysts at multiple brokerages forecasting Q3 2026 as a profit improvement inflection point. MLCC concept stocks were active on reports of AI-driven shortages and price surges. Humanoid robot concept stocks rebounded after a drone video suggested Tesla's Optimus production line in Texas may be nearing structural completion, targeting 2027 production with an annual capacity of 10 million units.
Read sourceChinese A-Share Markets Open Higher; Innovative Drug Stocks Surge, PCB Sector Rebounds
On September 21, China's A-share major indices opened higher, with MLCC, CRO, media, semiconductor, and military electronics sectors leading gains, while grain, coal, oil, precious metals, and tourism sectors declined. The innovative drug and CRO concept stocks saw a sharp rally, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit-up, and Harbin Pharmaceutical and Xinhua Pharmaceutical also hitting limit-up. The move follows the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese ministries, which sets targets including over 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, annual growth of over 20% for innovative drug industry scale, and over 200 innovative medical device approvals. Separately, PCB concept stocks rose after multiple institutional reports indicated that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC concept stocks were active amid reports of AI-driven shortages causing price surges. The humanoid robot concept rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese biotech stocks surge on new ten-year pharmaceutical industry plan
Chinese A-share markets opened higher on September 21, with the innovation drug and CRO sectors leading gains. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit the涨停 (daily limit-up). The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by China's Ministry of Industry and Information Technology and nine other departments. The plan sets targets for 2030: revenue of over 3.5 trillion yuan for large-scale pharmaceutical firms, annual innovation drug industry growth of over 20%, first-in-class drugs accounting for over 25% of the global share, over 200 innovative medical device approvals, and 20 pharmaceutical industrial parks with over 100 billion yuan in output. Separately, PCB stocks rose on reports of price renegotiations amid rising raw material costs, with analysts at multiple brokerages forecasting Q3 2026 as a profit improvement inflection point. MLCC stocks gained on AI-driven demand for high-capacity models, with spot prices reportedly surging several-fold. Humanoid robot concept stocks rebounded after a drone video suggested Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese A-Share Markets Open Higher; Innovation Drug Stocks Surge on New Five-Year Plan
Chinese A-share markets opened higher on September 21, with the MLCC concept, CRO concept, media, semiconductor, and military electronics sectors leading gains, while grain, coal, oil and gas, precious metals, and tourism sectors declined. Innovation drug and CRO concepts saw notable surges, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit-up, and Harbin Pharmaceutical and Xinhua Pharmaceutical also hitting limit-up. The rally followed the September 18 release of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments including the Ministry of Industry and Information Technology and the National Development and Reform Commission. The plan sets targets for 2030: revenue of over 3.5 trillion yuan for large-scale pharmaceutical enterprises, average annual growth of over 20% for the innovative drug industry, first-in-class drugs accounting for over 25% globally, over 200 innovative medical device approvals, and 20 pharmaceutical industrial parks with over 100 billion yuan in revenue. PCB concept stocks also rose after multiple brokerages forecast that price transmission mechanisms are functioning and that Q3 2026 will be an inflection point for sector profitability. MLCC concept stocks were active amid reports of AI-driven shortages causing price surges. Humanoid robot concept stocks rebounded following reports that Tesla's Optimus production line in Texas may be near structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina A-Share Market: Biotech Stocks Surge, PCB and MLCC Sectors Rally on Policy and Supply News
On September 21, China's A-share markets opened higher, with notable sector rotations. The innovative drug and CRO (Contract Research Organization) concept stocks surged, led by Nanhua Bio-medicine (000504) hitting its third consecutive daily limit-up, along with Harbin Pharmaceutical and Xinhua Pharmaceutical also hitting limit-up. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments, which set targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, annual innovative drug industry growth of over 20%, and 25% global share for first-in-class drugs. Separately, PCB (printed circuit board) stocks rose after multiple brokerage reports indicated that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC (multi-layer ceramic capacitor) stocks were active on reports of AI-driven shortages causing spot price surges. The humanoid robot concept rebounded after a drone video suggested Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese A-Share Markets Open Higher; Innovation Drug, PCB, MLCC Sectors Rally
Chinese A-share markets opened higher on September 21, with multiple sectors showing strong gains. The innovation drug and CRO concept sectors led the rally, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit their daily limits. The move follows the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth in innovative drug industry scale. The PCB sector rose on reports that manufacturers have begun re-quoting prices amid rising raw material costs, with analysts at multiple brokerages forecasting Q3 2026 as the inflection point for sector profitability. MLCC concept stocks also gained on reports of AI-driven shortages causing spot price surges. The humanoid robot concept rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina A-Share Markets Open Higher; Innovative Drug Stocks Surge, Humanoid Robot Concept Rebounds
China's A-share markets opened higher on September 21, with the MLCC concept, CRO concept, media, semiconductor, and military electronics sectors leading gains, while grain, coal, oil & gas, precious metals, and tourism sectors declined. The innovative drug and CRO concept stocks saw a sharp rally, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit up, and Harbin Pharmaceutical and Xinhua Pharmaceutical also hitting their daily limits. The rally was attributed to the release of the '15th Five-Year Plan' for the pharmaceutical industry by ten Chinese government departments, which set targets for the sector's revenue and innovation output by 2030. Separately, the PCB concept rose on reports of price renegotiations by manufacturers, and the MLCC concept was active due to AI-driven demand for high-capacity models. The humanoid robot concept rebounded, driven by news that Tesla's Optimus production line in Texas may be nearing structural completion, with a planned 2027 launch and annual capacity target of 10 million units.
Read sourceChinese biotech stocks surge as ten-department plan targets 20% annual innovation drug growth
Chinese A-share markets opened higher on September 21, with innovation drug and CRO concepts leading gains. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit their daily limits. The rally followed the September 18 release of the 'Pharmaceutical Industry Development 15th Five-Year Plan' by ten Chinese government departments including the Ministry of Industry and Information Technology and the National Development and Reform Commission. The plan sets targets for 2030: revenue exceeding 3.5 trillion yuan for large-scale pharmaceutical enterprises, annual innovation drug industry growth above 20%, first-in-class drugs reaching over 25% of global share, over 200 innovative medical device approvals, and 20 pharmaceutical industrial parks with 100-billion-yuan output. Separately, PCB stocks rose on reports of price renegotiations amid rising raw material costs, with analysts projecting Q3 2026 as a profit improvement inflection point. MLCC stocks gained on AI-driven high-capacity component shortages. Humanoid robot concept stocks rebounded following reports that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese Pharma Stocks Surge on Ten-Ministry Plan; PCB, MLCC, Humanoid Robot Sectors Rally
Chinese A-share markets opened higher on September 21, with several sectors experiencing notable gains. The innovation drug and CRO concepts led the rally, with Nanhua Bio-medicine (000504) hitting its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The surge followed the September 18 release of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' by ten ministries including the Ministry of Industry and Information Technology and the National Development and Reform Commission. The plan sets ambitious targets for 2030, including over 3.5 trillion yuan in revenue for large-scale pharmaceutical enterprises, annual innovation drug industry growth above 20%, and first-in-class drugs accounting for over 25% globally. Separately, the PCB sector rose on reports that manufacturers have begun re-quoting prices amid rising raw material costs, with analysts at multiple brokerages forecasting Q3 2026 as a turning point for sector profitability. MLCC components rallied on AI-driven demand for high-capacity models, with spot prices reportedly surging several-fold. The humanoid robot concept rebounded after a drone video suggested Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina's A-Share Market: Innovative Drug Stocks Surge, PCB and MLCC Sectors Rally on AI Demand
On September 21, China's A-share major indices opened higher, with innovative drug and CRO concept stocks leading gains. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit limit-up. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten central government departments, which set targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth for innovative drugs. Separately, PCB stocks rose after multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC concept stocks were active amid reports of AI-driven shortages causing spot prices to surge several times. Humanoid robot concept stocks rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese Innovation Drug Stocks Surge on New Five-Year Plan; Tesla Robot Line Nears Completion
On September 21, Chinese A-share markets opened higher, with innovation drug and CRO (Contract Research Organization) concepts leading gains. Nanhua Bio (000504) hit its third consecutive daily limit, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit their limits. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese ministries, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, 20%+ annual growth in innovative drug industry scale, and 25%+ global share of first-in-class drugs. Separately, PCB (Printed Circuit Board) stocks rose after multiple brokerages reported that manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC (Multi-Layer Ceramic Capacitor) stocks were active amid reports of AI-driven shortages causing price surges. Humanoid robot concept stocks rebounded on news that Tesla's Optimus production line in Texas may be near structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese biotech stocks surge; PCB, MLCC sectors rally on policy and price signals
Chinese A-share markets opened higher on September 21, with the innovation drug and CRO sectors leading gains. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit the daily limit. The rally follows the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth for innovative drug industry scale. Separately, the PCB sector rose after multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for profitability. MLCC stocks also gained on reports of AI-driven shortages causing price surges. The humanoid robot concept rebounded after a drone video suggested Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChinese A-Share Market Rises; Innovative Drug Stocks Surge, Tesla Robot Line Nears Completion
On September 21, China's A-share major indices opened higher, with innovative drug and CRO concepts leading gains. Nanhua Bio (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharma also hit limit-up. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten central government departments, which set targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and 20% annual growth for innovative drugs. PCB concept stocks rose after multiple brokerages reported that PCB manufacturers have begun re-quoting prices due to rising raw material costs, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC stocks gained on reports of AI-driven shortages causing spot price surges. Humanoid robot concept stocks rebounded after a drone video showed Tesla's Optimus production line in Texas nearing structural completion, targeting 10 million units annual capacity by 2027.
Read sourceChina's Innovative Drug Stocks Surge on Ten-Ministry Plan; PCB and MLCC Sectors Rally
Chinese A-share markets opened higher on September 21, with the innovative drug and CRO (Contract Research Organization) sectors leading gains. Nanhua Bio-medicine (000504) hit its third consecutive daily limit-up, while Harbin Pharmaceutical and Xinhua Pharmaceutical also hit their daily limits. The rally follows the September 18 release of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' by ten central government ministries, which sets targets including 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030, annual innovative drug industry growth of over 20%, and 200 innovative medical device approvals. Separately, the PCB (printed circuit board) sector rose after multiple brokerages forecast that upstream raw material price increases are prompting PCB manufacturers to re-quote, with Q3 2026 seen as a potential inflection point for sector profitability. MLCC (multi-layer ceramic capacitor) stocks also gained on reports of AI-driven shortages causing spot price surges. The humanoid robot concept rebounded on news that Tesla's Optimus production line in Texas may be nearing structural completion, targeting 10 million units annual capacity by 2027.
Read source